Cel-Sci Corporation(CELC)
Biotechnology company with a PI3K drug, Jedatolisib.
1 Insight
Investment Insights
AI-generated insights about Cel-Sci Corporation from various financial sources
Monday, July 28, 2025
Very Bullish
The company reported 'extremely potent and impressive' trial data. The speaker believes it is a 'buy' even after a large price increase, seeing potential for its drug to generate $1 billion in revenue.
Monday, July 28, 2025
Very Bullish
The company reported 'extremely potent and impressive' trial data. The speaker believes it is a 'buy' even after a large price increase, seeing potential for its drug to generate $1 billion in revenue.